DYADIC INTERNATIONAL INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
DYADIC INTERNATIONAL INC (DYAI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $28.35 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-25
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $28.35K, a 14.86% decline from fiscal 2024.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $33.30K.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $365.00K, a 78.90% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $28.35K 10-K · filed 2026-03-25 | |
| 2024-12-31 | $33.30K 10-K · filed 2026-03-25 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 | |
| 2022-12-31 | $365.00K 10-K · filed 2024-03-28 | |
| 2021-12-31 | $1.73M 10-K · filed 2023-03-29 | $1.73M 10-K · filed 2022-03-29 |
| 2020-12-31 | $481.14K 10-K · filed 2022-03-29 | |
| 2019-12-31 | $2.93M 10-K · filed 2021-03-30 | |
| 2018-12-31 | $39.36K 10-K · filed 2020-03-30 | |
| 2017-12-31 | $7.31K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |